BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing bromocriptine: Restrictions of indication regarding inhibition of lactation

2014.12.04

Active substance: bromocriptine

The marketing authorisation holders of medicinal products containing bromocriptine are circulating information that bromocriptine should only be taken in strengths up to 2.5 mg per individual dose for prevention or inhibition of lactation after childbirth, if medically indicated, e.g. in the case of intrapartum loss, neonatal death or HIV infection of the mother.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 1MB, File is accessible